Health Care

 

 

  PRESENTED BY 

 

 

Since the first offers in the Inflation Reduction Act's Medicare negotiation program went out, high level executives at companies subject to the process have made light of the suggested prices and the impact they'll have.

\u00a9 AP

 

What they're saying: AstraZeneca CEO Pascal Soriot told reporters last month that the initial offer from the Centers for Medicare and Medicaid (CMS) was "relatively encouraging," while Pfizer CFO David Denton told investors that the impact from negotiations would be "modest."

 

Far from cooling to the idea of negotiating the prices of their drugs, advocates see these comments as reassuring lip service to potentially anxious shareholders.

 

Merith Basey, executive director of the advocacy group Patients for Affordable Drugs, said, "We were expecting that they would come out and say something like this," noting the pharmaceutical industry could afford to lose a significant amount in the cost of their drugs while still remaining profitable.

 

These recent comments contrast with what pharmaceutical lawyers have said in court, lamenting the serious harm companies have already begun to experience due to negotiations, a claim that several federal judges have been dubious of.

 

“Their counsel have to follow certain ethical guidelines to talk about the harm while also making sure to comfort investors on the other side to say, ‘Hey, don’t run away from this business and these opportunities. It’s not going to be as bad as you think," Zachary Baron, director of the Health Policy and the Law Initiative at the O’Neill Institute, told The Hill.

 

While some drugmakers may not be anticipating extreme drops in price, at least when talking to investors, advocates stress that the impact on patients would still be immense.

 

"A few hundred dollars is a massive difference for one individual," Basey said. "Again, this is about ordinary people."

 

Welcome to The Hill’s Health Care newsletter, we’re Nathaniel Weixel and Joseph Choi — every week we follow the latest moves on how Washington impacts your health.

Did someone forward you this newsletter? Subscribe here.

 

How policy will be impacting the health care sector this week and beyond:

House Republicans ask for probe of unspent mental health funds

Drugmakers give surprising response to Medicare drug price offers

Trump says he’s ‘thinking in terms of’ 15 weeks on possible abortion ban

 

Upcoming news themes and events we're watching:

 

• The House Select Subcommittee on the Coronavirus Pandemic will hold a hearing Thursday on the of U.S. vaccine safety systems.

 

 

 

Express Scripts by Evernorth redefines savings and transparency with clear prescription cost breakdowns. Learn more.

 

Branch out with a different read: